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Current Trends and Future Implications in Sepsis
Treatment
Abstract: Sepsis is a systemic illness caused by invasion of tissues by pathogens. It is highly lethal, causing
circulatory failure and death. There has been extensive research trying to identify possible therapies for sepsis.
Apart from source control, and antibiotic and supportive therapy, glucocorticoids, anticoagulant agents, and
immunoglobulins have been tried in both the experimental setting and in septic patients. Newer strategies
include novel anticoagulant agents like ethyl pyruvate, statins, insulin receptor modulators and Toll-like
receptor modulators. This review article summarizes both the current therapies and endeavors for future
treatment in sepsis.
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Sepsis Tedavisindeki Güncel Gelişmeler
Özet: Sepsis, dokuların patojen organizmalar tarafından işgal edilmesi sonucu ortaya çıkan sistemik bir
hastalıktır. Dolaşım bozukluğu ve ölümle sonuçlanabilir. Sepsis tedavisi alanında birçok araştırma yapılmıştır.
Kaynak kontrolü, antibiyotik ve destek tedavisi dışında glukokortikoidler, immunoglobulinler, antikoagülan
ajanlar da hem deneysel hem de klinikte kullanılan tedavi yöntemleridir. Yeni tedavi stratejileri etil pirüvat gibi
antikoagülanları, statinleri, insülin ve toll-like reseptör modülatörlerini içermektedir. Bu makalede sepsisin hem
güncel tedavisi hem de gelecekte uygulanabilecek olası tedavi yaklaşımları tartışılmıştır.
Anahtar Sözcükler: Sepsis, glukokortikoidler, insülin, immunoglobulinler, antikoagülanlar, Toll-like
reseptörler
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For centuries, physicians have encountered the devastating consequences of infection
in forms of circulatory collapse and death. The link between bloodstream infection and
systemic illness is referred to as septicemia. Sepsis is a systemic illness caused by
microbial invasion of parts of the human body during the course of septicemia. It is
characterized by non-specific inflammatory responses with evidence of a microbial
origin. If hypoperfusion or dysfunction of at least one organ system accompanies, the
situation is called severe sepsis. Septic shock is diagnosed when severe sepsis is
complicated by hypotension unresponsive to fluid resuscitation and vasopressor therapy
becomes necessary (1).
The Centers for Disease Control (CDC) found the incidence of sepsis as 175.9 per
100,000 in 1989. This figure was found to be doubled when compared to 1979 owing
to the increased prevalence of patients with human immunodeficiency virus (HIV) and
acquired immunodeficiency syndrome (AIDS). The rates of sepsis in intensive care units
are cited to be between 4.5% and 26% (2).
In hospitalized patients, sepsis is a major cause of morbidity and mortality. The
mortality rate ranges between 30% and 50%, killing 250,000 patients every year in the
United States (3). The classical methods of treatment include the maintenance of
systemic perfusion and the eradication of infectious sources.
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There has been extensive research in the use of
alternative therapies directed at changing the disturbed
host responses that occur during sepsis. In sepsis,
infection rapidly activates systemic host defenses
including the complement, coagulation and kallikreinkinin systems as well as response of inflammatory cells,
which results in amplification of the immune response
with release of proinflammatory mediators. Platelet
activation and microvascular thrombi formation induce
localized tissue ischemia and contribute to the
inflammatory response. Endogenous anti-inflammatory
and anticoagulant factors are often insufficient to
counteract the effects of widespread inflammation and
tissue ischemia (4).
In the last decade, there has been a substantial effort
to identify factors in the host response to infection that
could be used for therapy. This review summarizes both
classic and novel approaches in sepsis treatment, in
chronological order.
Glucocorticoids:
Corticosteroids were proposed for the treatment of
patients with severe sepsis as early as 1940 (5). This is
based on the idea that septic shock may be complicated by
an adrenal insufficiency and a peripheral glucocorticoid
resistance syndrome. Diagnosis of adrenal insufficiency is
based on a cortisol increase after a corticotropin test of
less than 9 mg/dl. Using this definition, the prevalence of
occult adrenal insufficiency in severe sepsis was estimated
at about 50% and the 28-day mortality rate at about
75% (6).
In sepsis, the hypothalamic-pituitary adrenal axis is
activated through systemic and neural pathways.
Impaired adrenal function is responsible for the vessels’
decreased sensitivity to norepinephrine in severe sepsis
(7).
Cortisol inhibits the synthesis of various proinflammatory factors and prevents the migration of
inflammatory cells from circulation to tissues by blocking
the synthesis of chemokines, pro-inflammatory cytokines,
interferon (IFN)-γ, granulocyte macrophage colonystimulating factor, and tumor necrosis factor alpha (TNF-α)
(8).
By inhibiting inducible nitric oxide synthase (iNOS),
cortisol prevents endotoxin- induced venous insensitivity
to norepinephrine. This increases mean arterial pressure
and systemic vascular resistance, and improves mean
502
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arterial pressure responses to norepinephrine and
phenylephrine. Additionally, the need for vasopressor
therapy and duration of shock can be decreased (9).
Although the rationale for replacement therapy with
hydrocortisone in catecholamine-dependent septic shock
is growing stronger, a short course of high doses of
corticosteroids should not be administered in severe
sepsis, except in specific conditions as listed in Table 1.
(10).

Table 1. Indications for use of short-course, high-dose corticosteroids
in severe sepsis.
•

Typhoid fever

•

Pneumocystis carinii pneumonia in AIDS

•

Bacterial meningitis in children

Despite short course-high dose therapy, long courses
of low-dose corticosteroids reduce mortality at 28 days in
intensive care units, while they do not alter the risk of
gastroduodenal
bleeding,
superinfections
or
hyperglycemia. According to one study, hydrocortisone
(or equivalent steroid) could be given to patients with
septic shock immediately after they undergo an
adrenocorticotropin hormone test, at a dose of 200-300
mg, and should be continued for 5-11 days, only when
absolute or relative adrenal insufficiency is present (11).
In contradiction to the previously cited study,
corticosteroids did not make an impact on 28-day allcause mortality or on hospital mortality in severe sepsis
and septic shock. This was shown with a meta-analysis by
Annane et al. (12) of a subgroup of five trials studying
five-day courses of low-dose corticosteroids. The
evidence from eight trials did not support the use of short
course of high dose of corticosteroids in severe sepsis or
septic shock. However, the results in each of these studies
were heterogeneous.
A meta-analysis by Minneci et al. (13) published the
same year as Annane’s meta- analysis evaluating five
randomized clinical trials concluded that short courses of
high-dose glucocorticoids decrease survival during sepsis,
while 5- to 7-day course of physiologic hydrocortisone
doses with subsequent tapering increases survival rate
and shock reversal in patients with vasopressordependent septic shock.
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A recent prospective, randomized, double-blind,
single-center study in a postopera¬tive intensive care unit
in Brazil, which involved 29 patients with systemic
inflammatory response syndrome (SIRS), showed that
dexamethasone when administered as a single dose of 0.2
mg/kg improved the effects of vasopressor drugs and
respiratory functions, albeit it did not block the evolution
of SIRS (14).
Luce (15) recommends in his editorial that physicians
should wait for the ongoing clinical study carried out by
Sprung et al., called CORTICUS, which involves 800
patients, to test the hypothesis of whether
hydrocortisone would reduce 28-day mortality by 10% in
patients with septic shock whose cortisol levels do not
increase above 248 mmol/L in response to corticotropin
stimulation.
Immunoglobulins:
Despite the use of highly potent antimicrobial drugs,
owing to the inappropriate intrinsic defense mechanism
responses, many infections are still difficult to treat.
Either failed response or overwhelming response might
be responsible for treatment failure, which justifies the
endeavours in modulating host defenses to cope with the
insult. This modulation can be by inhibiting or enhancing
the immune response. Stimulation of anti-inflammatory
response and inhibition of proinflammatory response are
particularly useful in sepsis.
Immunoglobulins are humoral antibodies secreted by
B cells. Administration of intravenous immunoglobulins
(IVIG) has been shown to exhibit anti-inflammatory
properties. Although they induce proinflammatory
cytokines shortly after infusion, their major effect is a
downregulation of the inflammatory response (16).
Use of IVIG is a novel therapeutic effort to modulate
immune response in sepsis. IVIG might exert beneficial
effects in sepsis by several mechanisms (Table 2). IVIG
prophylaxis can undoubtedly reduce the occurrence of
infections, especially pneumonias, in high-risk patients
and is used for the treatment of streptococcal toxic shock
syndrome (17).
The history of IVIG use in sepsis dates back to 1981
(18), but there are still controversies surrounding their
use. In 2002, a Cochrane review found that polyclonal Ig
reduced mortality significantly among adults (19). A later
meta-analysis in 2004, stemming from the fact that Ig
had been the second largest drug cost in the author’s
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Table 2. Mechanisms of IVIG effects in sepsis.
•
•

Toxin inactivation
Neutralization of bacterial endotoxins, exotoxins and Gramnegative outer membrane proteins

•

Lipopolysaccharide (LPS) clearance

•
•

Increased LPS uptake in liver and spleen
Decrease in bacterial cell adherence, cell invasion, and organ
invasion

•
•

Stimulation of leukocyte and serum bactericidal activity
Neutrophil phagocytosis of E. coli in patients with Gram-negative
sepsis

•

Enhancement of serum opsonic activity

•
•

Neutralization of bacterial mitogenicity
Enhancement of Kupffer cell phagocytic function during the late
phase of sepsis and endotoxemia

•

Interference with cytokine effects

•

Prevention of excessive complement activation

hospital, concluded that polyclonal Igs should not be used
because a subgroup of four high-quality trials failed to
demonstrate a reduction in mortality (20).
Laupland et al. (21) in their meta-analysis of 14
randomized clinical trials revealed that there is significant
reduction in mortality in critically ill adult patients with
severe sepsis and septic shock treated with polyclonal
IVIG, although the methodological quality of the studies
were questionable.
Kreymann and colleagues (22) extended the previous
meta-analysis by including randomized controlled trials in
adults, children, and neonates. They reviewed a total of
27 studies and the data were summarized separately for
adults or older children and neonates. The authors
determined that the trend for adult patients was
composed of two approaches: using IgM- and IgAenriched IVIG preparations (IGAM) or preparations that
contained only IVIG. Their conclusion based on the data
was that the IGAM preparation reduced mortality in
adults by 34% and in neonates by 50%, leading them to
think that there is sufficient evidence to support the use
of such preparations in severe sepsis or septic shock.
The multicenter “score-based IgG therapy of patients
with sepsis” (SBITS) study by Werdan and colleagues (23)
using IVIG (n = 321) compared with human serum
albumin (n = 303) as placebo control did not show a
reduction in the 28-day mortality rate (39.3% vs.
503
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37.3%, respectively). This study outweighs all other
trials of IVIG in power and quality and can be considered
a landmark trial. Werdan et al. recommended that IVIG
should not be used as adjuvant in sepsis and septic shock,
at least in adult patients. As a result, reduction in
mortality seems to be due to IGAM more than by IVIG
alone. IVIG are widely used as prophylaxis against and as
supplemental treatment of sepsis and septic shock,
although they are not currently approved as medical
indications for IVIG products. More data are necessary to
ascertain whether this beneficial effect is linked with a
reduction of infection-related morbidity and mortality.
Anticoagulants:
Sepsis is associated with severe alterations in the
blood coagulation and fibrinolytic systems. Severe sepsis
is triggered by diverse pathogens that lead to secretion of
pro- and anti-inflammatory cytokines, activation and
mobilization of leukocytes, activation of coagulation and
inhibition of fibrinolysis. This results in disseminated
intravascular coagulation characterized by simultaneous
widespread microvascular thrombosis and profuse
bleeding from various sites.
Microvascular thrombosis then leads to tissue
hypoperfusion and multiorgan failure. There are a
number of endogenous pathways preventing thrombus
formation in humans, which include the fibrinolytic
system, antithrombin (AT), tissue factor pathway
inhibitor (TFPI), and the protein C-protein Sthrombomodulin pathway (24).
Intravascular fibrinolysis is mainly regulated by
plasminogen activator inhibitor (PAI).
PAI is a glycoprotein that is a member of the serine
protease inhibitor family. Its primary action is inhibition
of plasminogen activators, activated protein C (APC) and
thrombin, thus acting as a procoagulant. It is an acute
phase protein (25).
Sustained increased levels of PAI are associated with
worse outcomes in sepsis (26). There are genetic
polymorphisms in the gene encoding PAI that contribute
to the end result in sepsis and multi-trauma patients
(27,28).
In light of the aforementioned knowledge about PAI,
it could be stated that PAI deserves attention as a
potential therapeutic target in sepsis. Polymorphism
analysis to identify patients at increased risk and medical
inhibition of PAI are possible options for future therapy.
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A novel antithrombotic role for high molecular weight
kininogen is as an inhibitor of PAI function (29).
The other inhibitor of the fibrinolytic system is the
thrombin activatable fibrinolysis inhibitor (TAFI). TAFI is
synthesized in the liver and behaves as an antiinflammatory substance. It was shown to induce hepatic
necrosis in septic mice (30).
In a clinical study by Zeerleder et al. (31), it was
shown that septic patients have lower TAFI antigen levels
than normal controls. TAFI levels are stated to vary
between patients due to polymorphisms. The levels of
TAFI in circulation are also found to change between
Gram- negative and Gram-positive sepsis (32). Any solid
conclusion for TAFI as a possible treatment target can not
be derived from the recent literature. More research has
to be done for this purpose.
Tissue factor pathway inhibitor (TFPI) has been the
point of attraction in sepsis treatment for some time.
TFPI anticoagulates blood by both direct inhibition of
factor Xa and by the factor Xa-dependent inhibition of the
tissue–factor VIIa complex. The vast majority of the
endothelium is in the microcirculation; thus, the highest
levels of TFPI are also found in the microvasculature,
which gives this substance a pivotal role in the regulation
of microvascular thrombosis.
A phase 3 international trial with 1987 patients
assessing the therapeutic effect of TFPI concluded that
the therapy did not confer any survival benefit (33).
LaRosa et al. (34) further commented in their article that
protective mechanisms, dose, and the levels necessary to
achieve effects of TFPI have to be determined in new
trials. They criticized heparin in the previously mentioned
trial as a confounding factor and reported that patients
with severe pneumonia seem to be the subpopulation that
would benefit from the TFPI therapy.
The anticoagulant actions of antithrombin (AT) are
well known and are related to its function as an
endogenous serine protease inhibitor. AT is a hepatically
synthesized plasma protein.
It is rapidly consumed in sepsis by clearance with
other activated clotting factors (35). AT levels are further
diminished by enzymatic cleavage by neutrophil elastase
production and by diminished hepatic synthesis during
sepsis. In animal models of sepsis, AT III reduced the
mortality rate and limited or even prevented development
of organ dysfunction (36-40).
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Stemming from its well-known anticoagulant and
anti-inflammatory actions, an international clinical trial
was held on AT. Unfortunately, no overall benefit was
found by administration of 30 000 IU of plasma-derived
AT over 4 days in a trial involving 2314 patients. It was
observed that a prespecified subgroup of patients who
received no heparin appeared to have some modest
benefit from AT (P < 0.05) (41).
Despite findings of the trial, a later article evaluating
the efficacy and safety of the AT therapy pointed out that
treatment with high-dose AT may increase survival time
up to 90 days in patients with severe sepsis and high risk
of death and that the absolute risk reduction in sepsis
mortality was maintained despite an increase in bleeding
(42).
Activated protein C (APC) pathway is the classic
negative feedback loop of anticoagulation. Activation of
this pathway occurs along the surface of capillary
endothelial cells. This activation is catalyzed by thrombin
(43). APC is a potent serine protease and APC activity is
facilitated several-fold by reversible binding to another
hepatically synthesized, vitamin K-dependent protein
known as protein S.
In addition to inhibition of fibrin formation, APC also
promotes fibrinolysis in vitro by inhibiting two important
inhibitors of plasmin generation, namely PAI-1 and TAFI
(44).
APC has direct anti-inflammatory effects in
experimental studies that are independent of the
antithrombotic actions (45).
In vivo, the anti-inflammatory effects of APC include
inhibition of neutrophil adhesion, decreased TNF
elaboration, and decreased drops in blood pressure. APC
has multiple effects in tissue culture systems, including
limitation in nuclear factor (NF)-B-mediated
proinflammatory activity, inhibition of inflammatory
cytokine and chemokine generation, and upregulation of
antiapoptotic genes of the Bcl-2 family of homologs.
Microbial mediators like lipopolysaccharide (LPS) can
overcome the inhibition of apoptosis within endothelial
cells. APC protects endothelial cells from apoptosis in
experimental systems (46).
In experimental studies and in human sepsis,
circulating blood levels of protein C rapidly decline, with
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loss of this important coagulation inhibitor function (47).
The extent to which these protein C activators are
downregulated in severe sepsis appears to vary widely
(48).
These findings mentioned above provide the
therapeutic rationale for the administration of APC in
severely septic patients. In considering therapy with
protein C pathway components, protein C
supplementation is an obvious possibility, especially
because protein C levels are decreased, sometimes
severely, in severe sepsis.
In a phase 3 clinical trial called PROWESS (Protein C
Worldwide Evaluation in Severe Sepsis), recombinant
human APC administered by continuous infusion at a dose
of 24 μg/kg per hour for 4 days reduced the mortality
rate from 30.8% in the placebo group (n = 840) to
24.7% in the recombinant human APC group (n = 850;
P = 0.005). This indicates an absolute reduction in
mortality rate of 6.1% and a relative risk reduction of
19.4% associated with treatment with APC (49).
It was not long before the results of this trial met with
opposing views. One of the criticisms was about the
serious bleeding side effect of the drug, which occurred
in 5.3% of the patients with 0.4% mortality (50). The
other criticism concerned the obscure mechanism by
which APC affects survival improvement (51).
A second study sponsored by the same company that
supported the PROWESS study was held soon after the
PROWESS study, this time called ADDRESS
(ADministration of DRotrecogin alfa [activated] in Early
stage Severe Sepsis). This study was basically designed to
overcome the country-dependent limitations in indications
for use of APC (52).
A Cochrane review published in 2007 suggested that
APC should not be used in sepsis with an APACHE II score
of less than 25 in pediatric patients and warns policymakers, clinicians and academics to be cautious when
promoting the use of APC in patients with severe sepsis
and an APACHE II score of 25 or greater (53).
In addition to the above-mentioned data, a large
randomized, placebo-controlled trial with APC in pediatric
sepsis has recently been terminated prematurely because
of lack of efficacy (54). As a result, a randomized
controlled trial should be done before any conclusions
regarding its clinical use can be made.
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Future Implications for Sepsis Therapy
Anticoagulants:
Although APC is the only agent that is currently Food
and Drug Administration approved for treatment of
sepsis, several other agents look promising based on the
results of preclinical studies in animal models or
observational studies in patients.
One such compound is the ester ethyl pyruvate. The
biochemical basis for the effects of ethyl pyruvate in
animal models of sepsis is not completely understood. It
is known that ethyl pyruvate inhibits the activation of NFkB in in-vitro and in-vivo systems by covalently modifying
an essential sulfhydryl group in the protein (55).
A compound that is closely related to the tautomeric
form of ethyl pyruvate, called 2-acetamidoacrylate, has
been shown to have antiinflammatory properties both in
vitro and in vivo (56).
Venkataraman et al. (58) evaluated the effects of
ethyl pyruvate in a rat model of arterial hypotension
induced by the intravenous injection of LPS. The rats
were randomized to resuscitation with either ethyl
pyruvate solution or Ringer’s lactate solution.
Resuscitation with ethyl pyruvate solution significantly
prolonged survival time. Resuscitation with ethyl
pyruvate solution was also associated with significantly
lower circulating concentrations of nitrite or nitrate
(markers of nitric oxide synthesis) and interleukin (IL)-6,
and higher plasma levels of IL-10.
Ulloa et al. (59) investigated the effects of ethyl
pyruvate on LPS-induced inflammatory responses in vitro
and in vivo. In these studies, they found that ethyl
pyruvate inhibited the release of TNF and decreased levels
of TNF mRNA. Ethyl pyruvate blocked the activation of
the NF-kB and downregulated activation of p38 mitogen
activated protein kinase, which is another
proinflammatory intracellular signaling protein. The
effects of ethyl pyruvate in this study were significant
both before and after LPS challenge.
Insulin Receptors:
Glycogen synthase kinase-3 (GSK-3) belongs to the
family of serine/threonine kinases and phosphorylates
glycogen synthase leading to its inactivation, reducing
glycogen synthesis (59). Pharmacological inhibition or
genetic deletion of GSK-3β downregulates expression of
NF-kB-dependent genes (60).
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It is known that tight glucose control via
administration of insulin improves survival and decreases
organ dysfunction in critically ill patients. Insulin uses
GSK-3β in glucose regulation, but it is not clear whether
insulin exerts its effects in the critically ill via GSK-3β
(61). There are experimental sepsis models that utilize
selective GSK-3β inhibitors proving beneficial effects
(62).
Statins:
Statins are used in clinical practice for their lipidlowering effects, reducing cardiovascular morbidity and
mortality in patients with and without coronary disease.
In addition, statins have anti-inflammatory properties,
such as deactivating NF-kB and activator protein 1, which
are mediated by blocking the synthesis of isoprenoid
intermediates (63,64).
These intermediates serve as attachments for
intracellular signaling molecules. Statins interfere with
leukocyte endothelial cell interactions by downregulation
of the expression of integrin molecules, including CD11a,
CD18 and leukocyte function antigen 1 (65-67).
It is known that pre- or post-treatment with statins
improves survival in a murine model of sepsis (68), and
even when human volunteers were pretreated with
simvastatin before being injected with a small dose of
LPS, circulating levels of several proinflammatory
markers were significantly decreased (69). Decreased
expression of pathogen-associated molecular pattern
recognition receptors and Toll-like receptor (TLR) 2 and
TLR4 accompanied (70).
Almog et al. (71) reported in their prospective
observational cohort study in patients with acute bacterial
infections that former treatment with statins reduced the
rate of severe
sepsis and intensive care unit admissions. Thomsen et
al. (72) used a population-based surveillance cohort
design and demonstrated a significantly lower risk of
dying in statin users at 180 days after admission for a
bacteremic episode. Despite these two reports,
Fernandez et al. (73) showed higher hospital mortality
rates in statin-treated patients admitted with bacteremia.
In Canada, Hackam et al. (74) carried out a
population-based cohort analysis in which half of the
patients received a statin and half did not. The incidence
of sepsis was lower in patients receiving statins than in
controls even when confounding factors were eliminated.

Vol: 38

No: 6

Current and Future Sepsis Treatment

Toll-like Receptors (TLRs):
Innate immune recognition relies on a diverse set of
germ line–encoded receptors, termed pattern recognition
receptors (PRR), which recognize broad classes of
molecular structures common to groups of C1. TLRs are
the largest family of PRR (75). Cell surface TLRs
recognize bacterial, fungal and protozoan pathogens by
recognizing external molecules on these organisms.
Ligand binding to TLR results in conformational changes
leading to recruitment of adaptor proteins. Engagement
of these adaptors activate a series of signal transduction
molecules including IL-1R–associated kinases, TNF
receptor associated factor 6, transforming growth factor
β activated kinase, and the inhibitor of NF-κB kinase
complex. These events lead ultimately to activation of
many inflammatory pathways such as IFNs, TNF-α, IL-1,
IL-6, IL-10, IL-12 and chemokines (76-78).
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Septic shock is caused by TLR stimulation in the
setting of bacterial infection, leading to studies focusing
on TLR antagonists as potential therapies for this
condition (79).
Two TLR4 antagonists (E5564 and TAK-242) have
already been shown to be effective in the
prevention and treatment of LPS-induced shock in
animal models (80,81). Both were found safe in phase 1
and 2 clinical trials. In one clinical trial, E5564 protected
healthy adults from the physiological changes associated
with LPS challenge (82).
Phase 3 clinical trials will determine the effectiveness
of TLR4 antagonists in the treatment of patients with
sepsis.
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